CD79A and dengue disease: One study applied a SARS-CoV-2 IgG chemiluminescence assay to 84 samples from Brazilians with dengue and found no cross-reactivity (73), while a second applied two enzyme immunoassays for SARS-CoV-2 IgG or IgA and found 22% cross-reactivity (as compared to 4% false positivity in non-dengue infected controls) (74).